AAN: New Drug May Help Infants With Spinal Muscular Atrophy

Share this content:
AAN: New Drug May Help Infants With Spinal Muscular Atrophy
AAN: New Drug May Help Infants With Spinal Muscular Atrophy

THURSDAY, April 19, 2018 (HealthDay News) -- For infants with type 1 spinal muscular atrophy who have two copies of the survival motor neuron (SMN) 2 gene, RG7916 can increase SMN protein levels in the blood, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 27 in Los Angeles.

Giovanni Baranello, M.D., Ph.D., from the Carlo Besta Neurological Institute in Milan, and colleagues examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of RG7916 at different dose levels in 21 infants in an exploratory study.

The researchers identified a dose-dependent increase in SMN protein levels in blood; compared with baseline, there was up to a 6.5-fold increase after four weeks of treatment at the highest dose of RG7916 (range, 2.0 to 6.5). No safety-related stopping rules have been met to date; none of the patients had lost the ability to swallow, required tracheostomy, or reached permanent ventilation in limited follow-up. There were two fatal events, which were related to the disease and not related to the investigational drug.

"These results are exciting, as children with spinal muscular atrophy type 2, which is less severe than type 1, have approximately twice as much SMN protein as those with type 1, so to see an increase of up to 6.5 times the amount of protein is very encouraging and supports the possibility to see improved function in these babies," Baranello said in a statement.

The study was funded by F. Hoffmann-La Roche, the drug developer.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »